Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tight Glucose Control Slashes Heart Risks

By HospiMedica staff writers
Posted on 22 Jun 2005
Frequent self-monitoring of blood glucose that guides the use of at least three insulin injections a day can lower the risk of heart events by about 50% in people with type 1 diabetes, according to the results of a study presented at the annual meeting of the American Diabetes Association in San Diego (ADA, CA, USA) in June 2005.

A multicenter study called the Diabetes Control and Complications Trial (DCCT) found in 1993 that intensive glucose control greatly reduces the eye, nerve, and kidney damage of type 1 diabetes as well as the risk of atherosclerosis. More...
Now researchers have found that what is more impressive is the long-lasting value of tight glucose control.

In the new results announced at the ADA meeting, involving 1,375 volunteers who continued to participate in the study, the intensely treated patients had less than half the number of cardiovascular events found in the conventionally treated group of patients. Cardiovascular events included heart attacks, stroke, angina, coronary artery disease requiring angioplasty, or coronary bypass surgery.

"The risk of heart disease is about 10 times higher in people with type 1 diabetes than in people without diabetes. It's now clear that high blood glucose levels contribute to the development of heart disease,” observed David Nathan, M.D., of Massachusetts General Hospital (Boston, USA), co-chair of the DCCT trial and the EDIC (Epidemiology of Diabetes Interventions and Complications) study follow-up.

"There is a strong and growing body of evidence that everyone with diabetes gains from strict blood glucose control,” noted Catherine Cowie, Ph.D., who oversees EDIC for the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, MD, USA), which funded the studies.





Related Links:
Mass. General Hospital
NIDDK

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Radiofrequency Generator
GX1
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The study is the first to demonstrate a single nanomaterial platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration. (Image Credit: Stef Zingsheim/University of Sydney)

Nanobone Material Activates Natural Repair Signals to Regrow Bone

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.